MYC and Leber congenital amaurosis: Our findings may thus reflect (i) the numbers of MYC/MYCN amplified tumors observed in this cohort, or (ii) biological heterogeneity and/or subgroup-dependency, including the trial amendment to cease recruitment of patients with LCA tumors (see methods), potentially limiting ascertainment of tumors with interactions between these factors.